Cargando…

Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients

Regorafenib monotherapy is a potential option for metastatic colorectal cancer patients. However, the lack of predictive factors and the severe toxicities related to treatment have made its use in clinical practice challenging. Polymorphisms of VEGF and its receptor (VEGFR) genes might regulate angi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giampieri, Riccardo, Salvatore, Lisa, Del Prete, Michela, Prochilo, Tiziana, D’Anzeo, Marco, Loretelli, Cristian, Loupakis, Fotios, Aprile, Giuseppe, Maccaroni, Elena, Andrikou, Kalliopi, Bianconi, Maristella, Bittoni, Alessandro, Faloppi, Luca, Demurtas, Laura, Montironi, Rodolfo, Scarpelli, Marina, Falcone, Alfredo, Zaniboni, Alberto, Scartozzi, Mario, Cascinu, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846860/ https://www.ncbi.nlm.nih.gov/pubmed/27117754 http://dx.doi.org/10.1038/srep25195

Ejemplares similares

Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management
por: Del Prete, Michela, et al.
Publicado: (2015)

Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma
por: Bianconi, Maristella, et al.
Publicado: (2016)

The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment
por: D’Anzeo, Marco, et al.
Publicado: (2014)

The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management
por: Scartozzi, Mario, et al.
Publicado: (2012)

Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New
por: Faloppi, Luca, et al.
Publicado: (2016)

VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
por: Scartozzi, M, et al.
Publicado: (2013)

Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
por: Scartozzi, M, et al.
Publicado: (2012)

The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management
por: Faloppi, Luca, et al.
Publicado: (2014)

Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab
por: Scartozzi, Mario, et al.
Publicado: (2012)

Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis
por: Bittoni, Alessandro, et al.
Publicado: (2015)

Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab
por: Giampieri, Riccardo, et al.
Publicado: (2015)

The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy
por: Faloppi, Luca, et al.
Publicado: (2016)

Role of Vascular Endothelial Growth Factor (VEGF) and VEGF-R Genotyping in Guiding the Metastatic Process in pT4a Resected Gastric Cancer Patients
por: Scartozzi, Mario, et al.
Publicado: (2012)

Cancer Stem Cell Gene Profile as Predictor of Relapse in High Risk Stage II and Stage III, Radically Resected Colon Cancer Patients
por: Giampieri, Riccardo, et al.
Publicado: (2013)

Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis
por: Giampieri, Riccardo, et al.
Publicado: (2017)

Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer
por: Giampieri, Riccardo, et al.
Publicado: (2015)

Clinical Evidence for Three Distinct Gastric Cancer Subtypes: Time for a New Approach
por: Bittoni, Alessandro, et al.
Publicado: (2013)

The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib
por: Faloppi, Luca, et al.
Publicado: (2015)

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients
por: Scartozzi, M, et al.
Publicado: (2011)

Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter
por: Bianconi, Maristella, et al.
Publicado: (2019)

The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab
por: Demurtas, Laura, et al.
Publicado: (2017)

Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology
por: Aprile, Giuseppe, et al.
Publicado: (2015)

Neoadjuvant Therapy in Pancreatic Cancer: An Emerging Strategy
por: Bittoni, Alessandro, et al.
Publicado: (2014)

Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal?
por: Maccaroni, Elena, et al.
Publicado: (2015)

Optimal management of resected gastric cancer
por: Giampieri, Riccardo, et al.
Publicado: (2018)

Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis
por: Scartozzi, Mario, et al.
Publicado: (2009)

An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer
por: Giampieri, Riccardo, et al.
Publicado: (2021)

Urinary tract infections in women: etiology and treatment options
por: Minardi, Daniele, et al.
Publicado: (2011)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2020)

Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer
por: Berardi, Rossana, et al.
Publicado: (2010)

Predictors of Individual Response to Placebo or Tadalafil 5mg among Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: An Integrated Clinical Data Mining Analysis
por: Fusco, Ferdinando, et al.
Publicado: (2015)

The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
por: Ziranu, Pina, et al.
Publicado: (2021)

Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbidities
por: Hatzichristou, Dimitrios, et al.
Publicado: (2015)

ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
por: Marisi, Giorgia, et al.
Publicado: (2019)

The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer
por: Franco, Pierfrancesco, et al.
Publicado: (2018)

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report
por: Casadei Gardini, Andrea, et al.
Publicado: (2016)

From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy
por: Giampieri, Riccardo, et al.
Publicado: (2020)

A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer
por: Miyamoto, Yuji, et al.
Publicado: (2020)

Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia
por: Giampieri, Riccardo, et al.
Publicado: (2019)

Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer
por: Minardi, Daniele, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rgrq11kdfkotoar0j98cvqdq7m